Literature DB >> 25785163

Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report.

Yali Lv1, Wenbin Qian2.   

Abstract

We reported a rare case of pure red cell aplasia in a 44-year-old man with multiple myeloma with biclonal gammophathy (IgG lambda and IgA lambda type) with severe anemia. After treatment with bortezomib, adriamycin, and dexamethasone, the patient achieved very good partial response with disappearance of monoclonal gammopathy. However, his anemia was not significantly improved. Bone marrow analysis revealed selective erythroid hypoplasia. Thus, cyclosporine A was administered, which resulted in a complete recovery from anemia. The present case may provide some insight into the pathogenesis of PRAC and malignant plasma cell disorder.

Entities:  

Keywords:  Multiple myeloma; bortezomib; cyclosporine A; pure red cell aplasia

Year:  2015        PMID: 25785163      PMCID: PMC4358618     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  9 in total

1.  Paraproteinemic variety of pure red cell aplasia: immunological studies in 1 patient.

Authors:  L Resegotti; C Dolci; G Palestro; C Peschle
Journal:  Acta Haematol       Date:  1978       Impact factor: 2.195

Review 2.  Pure red cell aplasia.

Authors:  P Fisch; R Handgretinger; H E Schaefer
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

3.  Waldenström's macroglobulinaemia complicated by pure red cell aplasia: a case report.

Authors:  Yuan-Yuan Li; Lei Fan; Li Wang; Ji Xu; Jian-Yong Li; Wei Xu
Journal:  Blood Transfus       Date:  2013-05-27       Impact factor: 3.443

Review 4.  Where we were, where we are, where we are going: progress in multiple myeloma.

Authors:  P Leif Bergsagel
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

5.  A patient with myeloma who still has pure red cell aplasia despite the most intensive immune modulation.

Authors:  J Orchard; H Myint; T J Hamblin
Journal:  Leuk Res       Date:  1997-04       Impact factor: 3.156

Review 6.  Acquired pure red cell aplasia in Japan.

Authors:  S Mamiya; T Itoh; A B Miura
Journal:  Eur J Haematol       Date:  1997-10       Impact factor: 2.997

7.  The clinical aspects of biclonal gammopathies. Review of 57 cases.

Authors:  R A Kyle; R A Robinson; J A Katzmann
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

8.  The pathophysiology of pure red cell aplasia: implications for therapy.

Authors:  R J Charles; K M Sabo; P G Kidd; J L Abkowitz
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

Review 9.  Acquired pure red cell aplasia: updated review of treatment.

Authors:  Kenichi Sawada; Naohito Fujishima; Makoto Hirokawa
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

  9 in total
  4 in total

1.  Monoclonal gammopathy-associated pure red cell aplasia.

Authors:  Neha Korde; Yong Zhang; Kelsey Loeliger; Andrea Poon; Olga Simakova; Adriana Zingone; Rene Costello; Richard Childs; Pierre Noel; Samuel Silver; Mary Kwok; Clifton Mo; Neal Young; Ola Landgren; Elaine Sloand; Irina Maric
Journal:  Br J Haematol       Date:  2016-03-21       Impact factor: 6.998

2.  Clinical Resolution of Red Cell Aplasia Associated del 17p Multiple Myeloma, When Treated With Bortezomib and Dexamethasone.

Authors:  Abdullah Ladha; Yelena Fudym; Teresa C Gentile
Journal:  J Hematol (Brossard)       Date:  2017-01-10

Review 3.  Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Alexei Shimanovsky; Juliana Alvarez Argote; Shruti Murali; Constantin A Dasanu
Journal:  BBA Clin       Date:  2016-05-25

4.  Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide.

Authors:  Tomoki Ito; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Shosaku Nomura
Journal:  Leuk Res Rep       Date:  2018-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.